Introduction
Thyroid cancers are rapidly increasing endocrine malignancies. 18)
The reported frequencies of galectin-3 expression in DTC are presented in Table 1 .
Galectin-3 staining shows a strong diffuse cytoplasmic staining in most cases of PTC, including the conventional and follicular variant types (Fig. 1A) .
3) Galectin-3 is observed in 64-100% of patients with con- 
HBME-1
HBME-1 is a monoclonal antibody reacting against unknown antigens existing on mesothelial cell sur- [26] [27] [28] [29] HBME-1 is highly expressed in both PTC and FTC, but weakly expressed in MTC and anaplastic thyroid carcinoma (ATC). It is involved in cancer cell proliferation and migration.
25)

Fig. 2. HBME-1 immunostaining. (A) Papillary thyroid carcinoma exhibits a strong membranous staining (×200). (B)
Follicular thyroid carcinoma exhibits a diffuse cytoplasmic staining (×200). (C) Follicular adenoma shows focal expression of HBME-1 (×200).
In PTC, most cases show diffuse positive staining for HBME-1 (55-100%; mean, 88%). 2, 29, 30) In FTCs, HBME-1 detection showed a high variability between studies (50-100%; mean, 75%). 2,29-31) A few studies indicated HBME-1 staining in follicular patterned tumors of uncertain malignant potential that had either questionable vascular/capsular invasion or incomplete nuclear features of PTCs (29-66% of cases). 32, 33) Many studies reported the absence of HBME-1 in normal and hyperplastic thyroid. 2,33) However, HBME-1 has been detected in cases of adenomatous goiter (3-12%) and follicular adenomas (0-27%).
2,29,31-33) HBME-1 sensitivity, specificity, positive predictive value, and diagnostic accuracy in distinguishing benign from malignant lesions as a single marker are 80%, 96%, 96.7%, and 86.4%, respectively. 29) The results of reported HBME-1 staining in thyroid nodules by IHC are presented in Table 2 . Various HBME-1 staining patterns in either benign or malignant thyroid nodules are shown in Fig. 2 .
A meta-analysis of IHC markers, with a special focus on HBME-1, comprising 3900 samples reported that the diagnostic odds ratio (dOR) of HBME-1 (40.97) was higher than that of galectin-3 (23.41) and CK-19 (14.73). 11) dOR was estimated using sensitivity
and specificity values directly. This measurement shows the overall diagnostic power of each individual marker (a high dOR implies that the test presents a good diagnostic power).
11) HBME-1 positivity has been considered as a useful adjunctive marker in the discrimination of thyroid lesions using FNA cytology, due to its high sensitivity and specificity. 29, 34) However, its prognostic value is still in doubt and further studies are needed. staining of cytologic specimens should be interpreted with great caution because of its well-known reactivity in atypia and chronic lymphocytic thyroiditis that can be observed in PTCs.
CK-19
3)
BRAF
The V600E mutation of the BRAF gene is a wellknown genetic event in PTC and thought to be in- However, these methods are somewhat complex and expensive and often complicated by inadequate DNA preservation in formalin-fixed and paraffin-embedded tissues and by the presence of reactive thyroid parenchyma. [42] [43] [44] In a recent study, in which 144 patients with PTC were enrolled, the expression of the mutated BRAF V600E protein was evaluated with a novel mutation specific antibody, called clone VE1, using IHC. 41) They reported that 76 cases (52.8%)
showed definite diffuse cytoplasmic expression of the mutated protein and these selected cases were confirmed by sequencing analysis. 
Podoplanin
Podoplanin, a mucin-type transmembrane glycoprotein specific to the lymphatic channel is expressed in various human cancers, including colorectal, breast, and pancreas cancer, and is regarded as a factor promoting tumor progression. 14) Its expression by cancer-associated fibroblasts is known to be an indicator of poor prognosis in some types of cancer. In this review, we try to focus on the recent reports on the above-mentioned molecular markers, BRAF and RAS mutations, as well as RET-PTC and PAX8/ PPARγ rearrangements. Table 3 summarized DTC diagnosis efficacy of these four molecular markers in FNA specimens.
8)
BRAF Mutation
BRAF is a member of the mitogen-activated protein kinase (MAPK) pathway that is associated with cell proliferation, cell differentiation, and apoptosis. 50) Though many different BRAF mutations have been involved in the pathogenesis of several malignancies, a specific activating mutation resulting from the substitution of a glutamic acid for a valine at position 600 (V600E) has been observed in up to 50% of classic PTCs and 25% of its follicular variant (FVPTC). 51, 52) However, it was reported to be positive in only 16%
of thyroid cancers that presented an indeterminate or suspicious FNA cytology and PTC or FVPTC histology.
53)
The prevalence of the BRAF mutation in follicular thyroid carcinoma is just around 1%. 46) Thus, diagnostic testing for this mutation cannot serve as an independent cancer diagnostic marker in evaluation of indeterminate nodules. 46, 53) Nevertheless, it is promising as part of a panel. Despite a low sensitivity, BRAF mutation specificity is quite high with a false positive rate of only 0.2%. 54, 55) A more recent meta-analysis, summarizing the results of 6 studies and including 2800 malignant and benign lesions, reported a BRAF mutation specificity of 97.9% and a positive predictive value of 99.9%. Only seven false positive results were identified in three different studies. 56, 57) In term of prognostic value, a multicenter study showed a strong association of BRAF mutation with lymph node metastasis, extrathyroidal extension, manifestation in advanced disease (stages III and IV), and recurrence. 58) Additionally, BRAF mutation has previously been associated with the loss of radioiodine avidity of recurrent papillary thyroid cancer, making the disease refractory to radioiodine treatment. 58) Many studies indicated an association between BRAF mutation and decreased or negative expression of thyroid iodide-handling genes, including SLC5A5 (also known as NIS), thyroid stimulating hormone receptor (TSHR), SLC26A4 (also known as pendrin), TPO, and TG. 59, 60) BRAF mutation has also been shown to lead to the overexpression of many tumor-promoting molecules such as vascular endothelial growth factor (VEGF) and MET. 59, 60) These results provide the molecular basis for the aggressiveness and treatment failure of papillary thyroid cancer in association with BRAF mutation 61) and also suggest the strong association of BRAF mutation with papillary thyroid cancer mortality in an international multicenter study.
62)
RET/PTC Rearrangement
The most common types of chromosomal rearrangement in thyroid cancer are the intrachromosomal rearrangement like RET/PTC1 and RET/PTC3. 
RAS Mutation
The RAS oncogene family consists of 3 genes (HRAS, KRAS, and NRAS) that encode small GTPase proteins members of signal transduction. 46) Activating mutations in these genes stimulate the MAPK and PI3K/Akt pathways regulating cell growth, proliferation, differentiation, mobility, and mortality. 67) This mutation may be detected in up to 40% of However, Sahin et al. 70) reported that tumors with PAX8/PPARγ rearrangements usually carry a favorable prognosis.
Conclusion
The accurate diagnosis of thyroid nodule is the cor- 
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